

Cochlear / COH 2024 AGM report

ASX code	сон	
Meeting date	Friday, 25 October 2024	
Type of meeting	Hybrid	
Monitor	Patricia Beal with Gareth Eastwood	
Pre AGM-meeting	With Chair Alison Deans	

Meeting Statistics

Number of holdings represented by ASA	120
Number of shares represented by ASA	102,141
Value of shares represented by ASA	\$293m
Total number attending meeting	16 shareholders at physical; 23 online
Market capitalisation	\$18.6 billion
ASA open proxies voted	ASA voted in favour of all the resolutions

After a video about the social and health benefits to deaf seniors of cochlear implant(s), the meeting was opened with an explanation of questions and voting procedures. Chair Alison Deans and CEO Dig Howitt then gave their reports on a good year for COH.

Once the floor was open to questions, ASA complimented Cochlear on results for the year and long term. The strategy and executive rewards complement each other, and this is demonstrated in the long term results. ASA also questioned the Board's skills matrix "experience" rating for ESG. The Chair stated that the Board was comfortable with existing social and governance experience and was working on developing environmental sustainability expertise within Cochlear.

Responding to a question on market share, the CEO noted that there remains a significant opportunity within Australia, as there remains many people here who would benefit from an implant.

Research on drug eluting electrode (DEE) trials was discussed, such research taking years to progress but being promising. DEE is an electrode incorporating the drug dexamethasone, to

improve hearing outcomes for patients. Further info was also available on it and other aspects of COH's operations, after the AGM.

In response to an online question, the Chair stated that all proxy advisers and the ASA recommended voting in favour of the REM report.

All resolutions passed comfortably, with between 94 and over 99% approval. There were remarks about the good diversity of tenure within the Board, and succession planning. It was the last term Alison Deans expected to serve; while one Director who was recently appointed was elected at this meeting. Indeed, she disclosed in later conversation that her approval process had taken around 8 months, showing what care was taken.

ASA Disclaimer

This document has been prepared by the Australian Shareholders Association Limited ABN 40 000 625 669 ("ASA"). It is not a disclosure document, it does not constitute investment or legal advice and it does not take into account any person's particular investment objectives. The statements and information contained in this document are not intended to represent recommendations of a particular course of action to any particular person. Readers should obtain their own independent investment and legal advice in relation to the matters contemplated by this document. To the fullest extent permitted by law, neither ASA nor any of its officers, directors, employees, contractors, agents or related bodies corporate:

- makes any representations, warranties or guarantees (express or implied) as to the accuracy, reliability, completeness or fitness for purpose of any statements or information contained in this document; or
- shall have any liability (whether in contract, by reason of negligence or negligent misstatement or otherwise) for any statements or information contained in, or omissions from this document; nor for any person's acts or omissions undertaken or made in reliance of any such statements, information or omissions.

This document may contain forward looking statements. Such statements are predictions only and are subject to uncertainties. Given these uncertainties, readers are cautioned not to place reliance on any such statements. Any such statements speak only to the date of issue of this document and ASA disclaims any obligation to disseminate any updates or revisions to any such statements to reflect changed expectations or circumstances.